Physician profile
David Macpherson
NPI 1396276861
$857.92
in general payments reported to CMS, 2019-2025
10 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.63 · 2022: $108 · 2023: $258 · 2024: $300 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.38 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.08 | 2023-2025 | |
| Alcon Vision LLC | $105.01 | 2020-2025 | Rocklatan, Tryptyr, Clareon |
| Glaukos Corporation | $93.08 | 2022 | |
| Biotissue Holdings INC. | $74.19 | 2023-2025 | |
| Harrow Eye, LLC | $46.27 | 2024 | Vevye |
| Dompe US, INC. | $31.90 | 2024 | Oxervate |
| Bausch & Lomb Americas INC. | $31.79 | 2023 | Miebo, Prolensa, Vyzulta |
| Sight Sciences, INC. | $20.76 | 2024 | Tearcare System |
| Tarsus Pharmaceuticals, INC. | $17.85 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $14.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Macpherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.